# An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)

> **NCT07426419** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Affinia Therapeutics** · enrollment: 22 (estimated)

## Conditions studied

- Dilated Cardiomyopathy (DCM)
- BAG3 Mutation Associated Dilated Cardiomyopathy

## Interventions

- **GENETIC:** AFTX-201

## Key facts

- **NCT ID:** NCT07426419
- **Lead sponsor:** Affinia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2028-12
- **Final completion:** 2032-12
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07426419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07426419, "An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07426419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*